George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe earlier RNS re Elliott Investment taking 5% stake but seems a bit of an overreaction. But I’m not complaining!
Wow! Anyone know why this just happened @ 11.46?
This has been surprisingly strong in recent times (especially considering the markets have been weaker in general).
Did he jump or was he pushed?
Never a good sign to lose the CFO after a profit warning.
Buy for post COVID recovery or possible takeover.
considering i didn't want to be holding this crap in the first place, i once again find myself in the annoying position that if it keeps falling, i could put in a few grand and drop my average by over a pound, but, given i'm still well over a 700 average, it would still leave me massively in the red, just with a possible earlier exit point at break even.
for me this share has always been far to volatile, for a company that makes money, pays a dividend (even if it is pathetic) and has the potential for growth with a never ending clientele, and an expected shareprice of over 900-1000, it behaves far too much like an AIM penny share stock, this should not be a boom or bust investment
Just to make you feel better - my break even is higher than yours even though I bought a bucket full at 4.80p. Ah well, the AIM is high risk and we all know that. I’m still comfortable holding. New Chairman on the way might add a spark and I say again - this business makes a profit every year and for share holders that’s our main expectation met
My break even is 799p
I had set myself a 1000p sell price which it was tantalisingly close to.
I can wait….but it will not be getting more from me in the short term.
Has just waded in. Reckon you might get your £8 sooner than you expected Jatw. The vultures are circling but this is a profit making business with the potential for year on year growth. It won’t go cheaply
For lose interested in IL 2
https://www.drugtargetreview.com/article/71795/the-next-generation-of-cancer-immunotherapies-re-exploring-the-il-2-pathway/
Iovance can’t seem to agree with the FDA how to measure their therapy for approval purposes.
They have been rejected twice…..it seems per their website.
Whether this is just a delay or whether it becomes an existential issue for their TIL a therapy remains to be proven….the hope is there but delayed…
Anyway the market seems unimpressed.
This will either be a slow recovery or there could be a bid…..but the bid is unlikely to be at what management thought the company was worth a year ago…so my hunch is no bid and a wait of a couple of years to see this back above 800.
Can obviously see where you're coming from on your views on proleukin and it's clearly not doing what was expected of it which is why it's being called out, but what you're missing is the end goal which is the novel TIL therapies that the likes of Iovance are in the process of developing and which we've been told require the use of proleukin alongside it. Most scientific commentators are clear that TIL is the way forward and it will be a game changer in oncology, it's a question of when, not if. So Clinigen just need to sit on it for a little while and they have a whole brand new explosive market which could completely change this company and put it into the big league. I just hope there's no further silly acquisitions like the recent ones which don't seem to have added much or made sense, just need to keep adding in drugs like Erwinase which are low up front cost and make use of the infrastructure and capacity which has already been invested in.
That might make sense if there had been no global pandemic…..but there has.
It’s far from the only business to have had Covid impact yet you seem to be completely ignoring that!
It is certainly a jam tomorrow and the day after update….which may be intended to invite offers.
However I am getting more pessimistic about the prospects for Proleukin…..although it will probably cover its cost in the medium term it is not the great opportunity we were sold…..and competitors will soon be eating into its market…..hopefully it is lesson learned not to buy a product as its appeal wanes to its owner…..better to take a share of revenue and distribute rare disease medications outside US and China main markets… capital lite more predictable and a strength that can be grown.
Undervalued yes…..but PE will not be able to pay too much because the co is already loaded with debt…a good 2021/22 could see it rise back to 800, with further progress in 23. However there have been a number of mishaps in the last few years which is why it is around half the price it was when it acquired quantum pharma.
Yes that’s how I saw it too….future is bright
Perfect opportunity to invest in a good pharma business. Double digit gains expected in FY22, debt planned to be reduced to 2x by FY23 and bidders are circling. Whichever way you look at it, sp is hugely undervalued!!
is that articel anywhere that doesn't require forking over money to read it ?
Hoisting the for sale sign or white flag
https://www.thetimes.co.uk/article/could-a-bid-be-coming-for-clinigen-279wp9ggp
I don't imagine it's about the cash, and really just about getting rid of something that came as part of a package, that they never really wanted, and they don't think fits with the core business.
Don't really understand your question - but it sounds like your answering it yourself....not very profitable and non-core so they flogged it.
Bought for £150m in 2017, sold for £7.8 in 2021 - they say news comes in 3s so what’s next?
Do they need the cash? Seems they are selling for up to 7m an asset they hold at sale +9m
Does anyone know this subsidiary as part of quantum EBITDA as %of sales seems quite low margin.
The Board has not lost on their october 20 buys at just over 600. It would be good to see another concerted buy and inline numbers at the Next results.
Been a bit of a 'large-ish' seller after hours for the past few days/weeks. Has this been a common thing or is someone cashing in from the large drop?
Only question is....how much do they pay the cleaners at Schroders, Gartmore and Henderson? ;)